Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

Publication date: February 2019Source: The Lancet Haematology, Volume 6, Issue 2Author(s): Loretta J Nastoupil, Matthew A Lunning, Julie M Vose, Marshall T Schreeder, Tanya Siddiqi, Christopher R Flowers, Jonathon B Cohen, Jan A Burger, William G Wierda, Susan O'Brien, Peter Sportelli, Hari P Miskin, Michelle A Purdom, Michael S Weiss, Nathan H FowlerSummaryBackgroundTherapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advanced B-cell malignancies.MethodsWe did an open-label, phase 1 study with dose-escalation and dose-expansion phases, at five centres in the USA. Eligible patients were aged 18 years or older with histologically confirmed lymphocytic leukaemia or relapsed or refractory B-cell non-Hodgkin lymphoma, had measurable disease, adequate organ function, and an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less. Patients with known CNS lymphoma, active hepatitis B or C infection, or HIV were excluded. In the dose-escalation cohort, patients were treated in cycles of 28 days with escalating doses of oral umbralisib (400, 600, or 800 mg) and fixed doses of intravenous ublituximab (900 mg) and oral ibrutinib (420 mg for patients with chronic lymphocytic leukaemia; 560 mg for patients with B-cell non-Hodgkin lymphoma) in a standard 3 × 3 design until disease progression o...
Source: The Lancet Haematology - Category: Hematology Source Type: research

Related Links:

Publication date: Available online 21 November 2019Source: Journal of Cancer PolicyAuthor(s): Brandon Maser, Lisa M. Force, Paola Friedrich, Federico Antillon, Ramandeep S. Arora, Cristian A. Herrera, Carlos Rodriguez-Galindo, Rifat Atun, Avram DenburgAbstractTo help understand how health systems and sociopolitical contexts intersect with and impact the performance of childhood cancer care in low- and middle-income countries (LMICs), we have developed a systems-level framework for analyzing the performance of LMIC childhood cancer programs within their health system contexts: The Paediatric Oncology System Integration Tool...
Source: Journal of Cancer Policy - Category: Cancer & Oncology Source Type: research
Future Oncology, Ahead of Print.
Source: Future Oncology - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Source: Cancer Biotherapy and Radiopharmaceuticals - Category: Cancer & Oncology Authors: Source Type: research
Date: Thursday, 12 19, 2019; Speaker: Cristine Delnevo, Ph.D., M.P.H., F.A.A.H.B., Director, Center for Tobacco Studies, Society and Policy Rutgers School of Public Health; Nir Eyal, D.Phil, Director, Center for Population-Level Bioethics (CPLB), Society and Policy Rutgers School of Public Health; https://epi.grants.cancer.gov/events/enrich-forum/
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Tuesday, 12 03, 2019; Speaker: Erikka Loftfield, Ph.D., M.P.H., Research Fellow, Division of Cancer Epidemiology and Genetics (NCI); https://metabolomics-sig.nih.gov/events.html
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Monday, 12 09, 2019; Speaker: Sharon Cantor, Dr., University of Massachusetts Medical School; Building: Building 31; 2A48
Source: NIH Calendar of Events - Category: American Health Source Type: events
CONCLUSION: This mini-review will explain the present research status of Apigenin and will further throw some light on how Apigenin performs its anti-cancerous actions by interfering with the key cell-signaling pathways. PMID: 31746310 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Cancer Drug Discovery - Category: Cancer & Oncology Tags: Recent Pat Anticancer Drug Discov Source Type: research
Nanomedicine, Ahead of Print.
Source: Nanomedicine - Category: Nanotechnology Authors: Source Type: research
CONCLUSIONS: Our observations indicate that treatment of Hep-2 laryngeal cancer cells with ELFEMF for 30 min at 25-50 mT and EP Au-NPs can cause cell damage inducing apoptosis and cell cycle arrest. PMID: 31746453 [PubMed - as supplied by publisher]
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
More News: Atrial Fibrillation | Bleeding | Cancer | Cancer & Oncology | Cellulitis | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Cough | Diarrhoea | Gastroenterology | Headache | Hematology | Hepatitis | Hepatitis B | Hodgkin's Disease | Leukemia | Lymphoma | Migraine | Non-Hodgkin's Lymphoma | Oral Cancer | Pain | Pain Management | Pneumonia | Skin | Study | Toxicology